Sk Biopharmaceutica Financials
| 326030 Stock | 103,800 500.00 0.48% |
326030 |
Understanding current and past Sk Biopharmaceutica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sk Biopharmaceutica's financial statements are interrelated, with each one affecting the others. For example, an increase in Sk Biopharmaceutica's assets may result in an increase in income on the income statement.
Please note, the presentation of Sk Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sk Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sk Biopharmaceutica's management manipulating its earnings.
| Foreign Associate | Korea |
| Instrument | Korea Stock View All |
| Exchange | Korea Stock Exchange |
| ISIN | KR7326030004 |
| Business Address | 221, Pangyoyeok-ro, Seongnam-si, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.skbp.com |
| Phone | 82 31 8093 0114 |
You should never invest in Sk Biopharmaceutica without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of 326030 Stock, because this is throwing your money away. Analyzing the key information contained in Sk Biopharmaceutica's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sk Biopharmaceutica Key Financial Ratios
Sk Biopharmaceutica's financial ratios allow both analysts and investors to convert raw data from Sk Biopharmaceutica's financial statements into concise, actionable information that can be used to evaluate the performance of Sk Biopharmaceutica over time and compare it to other companies across industries.| Return On Equity | -0.12 | |||
| Return On Asset | 0.0475 | |||
| Target Price | 96154.0 | |||
| Number Of Employees | 10 | |||
| Beta | 1.11 |
326030 Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sk Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Sk Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sk Biopharmaceutica competition to find correlations between indicators driving Sk Biopharmaceutica's intrinsic value. More Info.Sk Biopharmaceuticals Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sk Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sk Biopharmaceutica's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sk Biopharmaceuticals Systematic Risk
Sk Biopharmaceutica's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sk Biopharmaceutica volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Sk Biopharmaceuticals correlated with the market. If Beta is less than 0 Sk Biopharmaceutica generally moves in the opposite direction as compared to the market. If Sk Biopharmaceutica Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sk Biopharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sk Biopharmaceutica is generally in the same direction as the market. If Beta > 1 Sk Biopharmaceutica moves generally in the same direction as, but more than the movement of the benchmark.
Sk Biopharmaceutica December 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sk Biopharmaceutica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sk Biopharmaceuticals Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sk Biopharmaceuticals Co based on widely used predictive technical indicators. In general, we focus on analyzing 326030 Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sk Biopharmaceutica's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 12.81 | |||
| Value At Risk | (4.17) | |||
| Potential Upside | 5.77 |
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stocks Directory Find actively traded stocks across global markets |